Two Landmark ADC Out-Licensing Deals with Similar Terms Highlight Radiance Biopharma's Strategic Partnerships

Sep 04, 2025 10:05 CST Updated 10:06

Novatim

Innovative Drug Developer for Tumor Immunotherapy

CSPC

Innovative Drug Research and Development, Manufacturer

▲November 6-7The 10th Guangzhou (Greater Bay Area) BiomedicalInnovators Summit Scan to register

Note:This article does not constitute any investment opinions or suggestions; please refer to official/company announcements for accuracy.This article only introduces drugs related to medical health, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.

PharmaCircleMonitoring shows: On August 29, 2025, Novatim andRadianceBiopharma Reaches Exclusive BD Licensing Collaboration, Granting Radiance Overseas Development, Registration, and Commercialization Rights for KY-0301, the World’s First Nano Bispecific ADC Drug, with a Total Value of up to US$1.165 Billion.

According to the terms of the agreement:

(1) Novatim will receive a $15 million upfront payment;

(2) Up to US$150 million in development and registration milestone payments;

(3) Up to USD 1 billion in commercial milestone payments;

(4) At the same time, a progressive sales share will be obtained based on the annual net sales in the authorized region.

The total amount of this BD&L deal can reach up to 1.165 billion US dollars at most.The candidate molecule KY-0301 is based onMET and EGFRThe broad-spectrum high expression and differentiated innovative design of KY-0301 are expected to bring new breakthroughs in the treatment of non-small cell lung cancer, colorectal cancer, and squamous cell carcinoma of the head and neck.

On February 19, 2025, CSPC's subsidiary Jushi Biopharmaceuticals entered into an exclusive licensing agreement with Radiance Biopharma for SYS6005.Radiance Biopharma Obtains Recombinant Anti-Human Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1) Antibody-drug conjugate SYS6005 exclusive rights for development and commercialization in the United States, the European Union, the United Kingdom, Switzerland, Norway, and other regions.SYS6005Is a targetedROR1TheADC, adoptMMAEAs a toxin, and utilizing the enzyme-catalyzed site-specific antibody conjugation technology of CSPC PHARMACEUTICAL GROUP LIMITED.

For thisBD&LTransaction:

(1) CSPC Jushi received a down payment of 15 million US dollars;

(2) and is entitled to receive up to US$150 million in potential development and regulatory milestone payments;

(3) Up to $1.075 billion in sales milestone payments;

(4) Will charge according to the productProduct Origin: This PlaceTiered sales commission calculated based on the district's annual net sales.

CSPC's clinical pipeline covers multiple fields such as oncology, neurology, cardiovascular, and autoimmune diseases. Technologically, CSPC claims to have eight innovative technology platforms under its umbrella (nanoparticle formulations, long-acting injectables, mRNA, siRNA, ADC, monoclonal antibodies, bispecific antibodies, PROTAC, and other R&D technology platforms).The industry is paying close attention to the company's potential EGFR ADC deals.

According to the monitoring of PharmaCircle: Radiance Biopharma and BioRay Biotech reached an exclusive option and licensing agreement regarding bispecific ADC in January this year.Not yet viewed。

Radiance Biopharma, headquartered in Boston, Massachusetts, USA, focuses on developing a pipeline of antibody-based cancer therapeutics, including mono-specific and bi-specific antibody-drug conjugates (ADCs), to treat cancer and address other unmet medical needs. Marc Lippman, MD, is the co-founder and Chairman of the Board of Radiance Biopharma. He is a renowned oncology expert and has also been a leader in the ADCs field.SeagenInc. (acquired by Pfizer Inc. in December 2023), a founding board member.

References:

Moxie Pharma Data pharma.bcpmdata.com (formerly PharmaCloud Data);

https://www.e-cspc.com/details/details_92_6667.html；

www.radiancebiopharma.com; etc.

The following is the content of the header image meeting

Note: Scan the code immediately to join the PharmCircle communication group.

Rooted in Shanghai and radiating globally, PharmaCircle serves as a strategic platform for the biopharmaceutical industry. With the mission of "enabling the borderless flow of intelligence and networks," it has established an empowerment system covering the entire pharmaceutical industrial chain, including R&D, production, distribution, and commercialization. Through four core engines—intelligent cloud services, precise resource linking, industry think tanks, and ecosystem communities—it is building the infrastructure for the flow of pharmaceutical value in China.

Under the dual waves of globalization and digitalization, PharmaCircle is redefining the circulation paradigm of pharmaceutical resources—this is not only a hub for information and networking but also a catalyst for industrial transformation. With China as the origin, we are weaving a global network of pharmaceutical intelligence, making every precise connection a catalyst for enterprises' leapfrog growth.

Like

Share

Recommended Points